GB2329334A — Cholesterol-lowering agents
Assigned to Reckitt Benckiser Healthcare UK Ltd · Expires 1999-03-24 · 27y expired
What this patent protects
A composition comprising a) a HMG CoA reductase inhibitor, and b) a bile complexing agent. for the reduction of cholesterol in plasma. The inhibitor is preferably a station or fibrate. The complexing agent is preferably fibrous and selected from biopolymers and starches. Exemplif…
USPTO Abstract
A composition comprising a) a HMG CoA reductase inhibitor, and b) a bile complexing agent. for the reduction of cholesterol in plasma. The inhibitor is preferably a station or fibrate. The complexing agent is preferably fibrous and selected from biopolymers and starches. Exemplifield are compositions containing (a) fluvestatin and isphaghula husk; (b) fenofibrate and polyacrylic acid carbomer; (c) pravastatin and isphaghula husk.
Drugs covered by this patent
- Zetia (EZETIMIBE) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.